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INTRODUCTION
Blood pressure (BP) control is important in preventing the progression of cardiovascular damage in hypertensive patients. 1 However, it is difficult for a single class of antihypertensive drugs to achieve effective BP reduction in a majority of hypertensive patients. 2, 3 Therefore, combination therapies with two or more antihypertensive drugs are often required in the management of hypertension. 4, 5 However, in Japan, many patients with uncontrolled BP only receive one class of antihypertensives, 6 although combination therapy is encouraged.
One of the best combinations is that of a renin-angiotensin system (RAS) inhibitor and a low-dose thiazide diuretic because effectiveness and safety have been proven for them. [7] [8] [9] In a retrospective study that was conducted in older women, treatment with a combination of an angiotensin-converting enzyme (ACE) inhibitor and a thiazide diuretic showed a decreased probability of mortality from cardiovascular disease. 10 Recent reports suggest that the combination of a RAS inhibitor and diuretic can be useful even in diabetic 11 and very old 12 patients. In the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation) trial, 11 a combination of perindopril and indapamide significantly decreased BP levels and the primary end point (macroangiopathy and microangiopathy) relative to placebo without adverse metabolic effects in patients with type II diabetes mellitus. The HYVET (Hypertension in the Very Elderly Trial) 12 showed that the perindopril plus indapamide combination has advantages over placebo in hypertensive patients aged 80 years or more. Therefore, combination therapy including a RAS inhibitor and a diuretic is considered one of the most powerful antihypertensive strategies developed for preventing hypertension-induced cardiovascular injury in a wide range of hypertensive patients. In Japan, few clinical trials have examined combination treatment with a low-dose thiazide diuretic and a RAS inhibitor for the management of hypertension, chiefly because thiazide diuretics are not commonly used. 2 However, because the combination of diuretic and angiotensin II type 1 receptor blocker (ARB) drugs has recently become available, it is important to determine whether combination therapy with an ARB and a diuretic is useful in Japanese hypertensive patients who are resistant to a single class of antihypertensive other than a RAS inhibitor or a diuretic.
Calcium channel blockers (CCBs) are the most frequently used medication in Japan. However, a single dose of a CCB effectively decreases BP to o140/90 mm Hg in only B40% of patients with hypertension, 2 and an alternative or additional antihypertensive drug is required in the remaining 60% of patients. An ARB-thiazide diuretic combination drug therapy may be a candidate as an alternative antihypertensive to CCB because of its effectiveness. Therefore, we evaluated the effectiveness of switching from therapy with a CCB to combination with an ARB and a low-dose thiazide diuretic. As some investigators have reported that the antihypertensive effect of telmisartan plus hydrochlorothiazide was superior to that of losartan plus hydrochlorothiazide, the elements of a first generation combination drug in Japan, 13, 14 we compared the effects of the treatment with telmisartan plus hydrochlorothiazide and continuous administration of amlodipine, which is the most popular CCB, in patients with uncontrolled BP undergoing treatment with 5 mg per day of amlodipine for X3 months.
METHODS Participants
This study was carried out at the Tokyo University Hospital and a few other hospitals in Japan from June 2007 to May 2008. This study was approved by the Institutional Review Boards of The University of Tokyo Clinical Research Center and the other hospitals, and was undertaken in accordance with the principles of the Declaration of Helsinki. Written informed consent was obtained from all patients.
The enrollment criteria for hypertensive patients included: (1) outpatient systolic and diastolic BPs of more than 140/90 mm Hg; (2) treatment with 5 mg per day of amlodipine for X3 months; and (3) age between 20 and 80 years. Exclusion criteria were: (1) secondary hypertension, including a solitary kidney or bilateral renovascular hypertension; (2) taking antihypertensives other than amlodipine, including loop diuretics; (3) cerebro-reno-cardiovascular disease that had occurred within 6 months; (4) a serum creatinine level of 42.0 mg per 100 ml; (5) a BP level of more than 180/110 mm Hg; (6) class III or IV heart failure (NYHA (New York Heart Association) classification); (7) contraindication of telmisartan (hypersensitivity to telmisartan, pregnant women and severe liver damage) or hydrochlorothiazide (hypersensitivity to thiazide, anuria, acute renal failure and apparent decrease in body sodium or potassium levels); (8) hyperkalemia (45.5 mequiv. l À1 ) or hypokalemia (o3.5 mequiv. l À1 ); (9) untreated (47.0 mg per 100 ml) or uncontrolled (48.0 mg per 100 ml with medication) hyperuricemia; and (10) uncontrolled diabetes mellitus (glycosylated hemoglobin A1c (HbA1c) 49.0%) or hypoglycemia (o50 mg per 100 ml or hypoglycemic symptoms).
Interventions
The participants were randomly allocated to two groups, namely those whose treatment was switched to 40 mg per day of telmisartan plus 12.5 mg per day of hydrochlorothiazide (TH) or those who continued treatment with amlodipine (Am). Randomization was performed according to minimization methods on the basis of stratification of age, body mass index (BMI) and baseline BP. The target BP for the study was o140/90 mm Hg. BP levels were measured according to the Japanese Society of Hypertension Guidelines for Management of Hypertension. 11 If the treatment failed to reduce BP to the target level, telmisartan was increased to 80 mg per day in the TH group and amlodipine was increased to 7.5 mg per day in the Am group.
Outcome measures
The primary end point was change in office BP. In addition, we measured office pulse rate and BMI. The following laboratory findings were also measured: fasting blood glucose, fasting serum insulin, HbA1c, total serum cholesterol, triglycerides, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, liver enzymes (g-glutamine transferase, aspartate aminotransferase, alanine aminotransferase and alkaline phosphatase (ALP)), creatinine, blood urea nitrogen, uric acid and electrolytes (sodium (Na) and potassium (K)).
Statistical analysis
Data were analyzed according to randomized treatment assignments of participants, regardless of their subsequent medication status (intention-totreat analysis). Data were presented as means ± s.d. The mean values in the two groups were compared using unpaired t-tests or w 2 -tests. ANOVA (analysis of variance) with repeated measurements was applied to test the effect of treatment on BP. Statistical significance was set at Po0.05.
RESULTS

Study population
A total of 75 participants were enrolled in this study. They were allocated to either the TH group (n¼37) or the Am group (n¼38). Table 1 shows baseline characteristics of the participants in the two groups. Systolic (TH and Am groups: 151.5±8.8 vs. 150.6±9.0 mm Hg, respectively) and diastolic (82.3 ± 9.0 vs. 83.6 ± 8.3 mm Hg, respectively) BP levels were not different between the two groups ( Figure 1 ). The mean BP was also similar between the TH and Am groups (105.4±6.7 vs. 105.9±6.2 mm Hg, respectively). There were no significant differences between the two groups, except for slight increases in pulse rate and ALP in the TH group. Baseline serum uric acid was marginally (P¼0.069) higher in the TH group (Table 1 and Figure 2 ). The frequency of coexisting illness did not differ between the TH and Am groups ( Table 2 ). Diabetes and/or dyslipidemia was present in 28 (75.7%) patients in the TH group and in 26 (68.4%) patients in the Am group. The frequencies of statin use (14 (37.8%) vs. 12 (31.6%, respectively)) and antidiabetic agent use (13 (35.1%) vs. 16 (42.1%, respectively)) were also not different. The average final dose of telmisartan was 44.5±8.8 mg per day and that of amlodipine was 5.9 ± 0.7 mg per day. During treatment, one patient from the TH group (violation of the protocol) and three patients from the Am group (discontinuation: n¼2, violation of the protocol: n¼1) were excluded from the study. Telmisartan and hydrochlorothiazide vs. amlodipine K Ando et al during the treatment in both groups, but the extent of decrease was significantly greater in the TH group (Po0.01). The decrease in diastolic BP was not significant and its extent was marginally greater than that in the TH group (P¼0.20). After 12 weeks of treatment, the decreases in systolic (À18.5 ± 16.9 vs. À6.4 ± 10.9 mm Hg, Po0.01, respectively) and mean (À9.9±11.4 vs. À3.7±8.9 mm Hg, Po0.02, respectively) BP levels were significantly greater in the TH group, and the change in diastolic BP was slightly, but not significantly, higher in the TH group (À5.6±10.7 vs. À2.3±9.5 mm Hg, P¼0.12, respectively). The small changes in diastolic BP may be due to the fact that the average pretreatment levels of diastolic BP were already normal ( Figure 1 
Laboratory data
Glucose levels and lipid metabolism were not different between the TH and Am groups (Table 3) . Although serum K was not different, serum uric acid was higher (Po0.01) in the TH group. Serum uric acid was significantly increased in the TH group, but not in the Am group (Figure 1 ). A total of 10 patients in the TH group and 4 patients in the Am group (P¼0.13) showed abnormally high uric acid levels.
Adverse events
Four adverse events (light-headedness on standing, vertigo, headache and dermal pruritus) were observed in the TH group, and six (heaviness of the head, vertigo, anxiety attack, bone fracture, gout attack and fundal hemorrhage) were observed in the Am group. None of the patients discontinued participation because of the abovementioned adverse events.
DISCUSSION
In this study, we showed that combination therapy with telmisartan plus low-dose hydrochlorothiazide has a superior antihypertensive effect relative to amlodipine monotherapy. Therefore, these results support the claim that patients with uncontrolled hypertension undergoing treatment with amlodipine monotherapy may benefit from alternative antihypertensive strategies to achieve target BP control, including initiation of combination therapy with telmisartan plus low-dose hydrochlorothiazide. Our data are in agreement with the results of the ATHOS (A Comparison of Telmisartan plus Hydrochlorothiazide with Amlodipine plus Hydrochlorothiazide in Older Patients with Predominantly Systolic Hypertension) study, 15 in which the combination of telmisartan plus hydrochlorothiazide decreased ambulatory BP to a greater extent than did amlodipine plus hydrochlorothiazide. In this study, even in combination with a thiazide diuretic, amlodipine showed a smaller depressive effect on BP than did telmisartan plus hydrochlorothiazide. The antihypertensive effects of RAS inhibitors are greatly enhanced with salt depletion. In fact, the addition of low-dose hydrochlorothiazide doubled the antihypertensive effect of losartan. 16 Similarly, hydrochlorothiazide greatly enhances the BP depressor effects of telmisartan. 17, 18 Moreover, in mild-to-moderate hypertensive patients who did not respond to telmisartan monotherapy, the addition of low-dose hydrochlorothiazide effectively decreased BP in the first 4 weeks of use. 18 More importantly, the antiproteinuric effects of ACE inhibitors are blunted with salt excess, but the addition of hydrochlorothiazide suppresses the salt-induced increase in urinary protein. 19 Moreover, in the GUARD (Gauging Albuminuria Reduction with Lotrel in Diabetic Patients With Hypertension) trial, 20 benazepril plus hydrochlorothiazide showed superior antialbuminuric effects relative to benazepril plus amlodipine. Thus, the combination of a RAS inhibitor and a thiazide diuretic may be beneficial, especially in hypertensive patients with kidney disease. In addition, the combination of a RAS inhibitor and a thiazide diuretic has been shown to be useful even in patients with type II diabetes mellitus 11 and in very old patients with hypertension. 12 Despite its effectiveness, increases in the number of antihypertensive drugs may suppress compliance. Combination drugs can resolve this problem; a recent report 21 indicated that the percentages of patients taking combination drugs with lisinopril plus hydrochlorothiazide and with enalapril plus hydrochlorothiazide were significantly greater (18.8 and 21.7%, Po0.05, respectively) than the percentages of patients taking lisinopril plus concurrent diuretic therapy and enalapril plus concurrent diuretic therapy.
Glucose levels and lipid metabolism were similar between the two groups, although the study population included a number of patients with metabolic disorder. Although treatment with thiazide diuretics raises concerns regarding deteriorating glucose and lipid metabolisms, low-dose diuretics such as 12.5 mg per day of hydrochlorothiazide do not significantly alter serum lipid and blood glucose levels. 22 The metabolically harmful effects of thiazide diuretics are believed to be mostly due to hypokalemia. A meta-analysis of patients treated with a thiazide diuretic showed that serum potassium was inversely correlated with blood glucose. 23 A dose of 12.5 mg per day of hydrochlorothiazide is sufficient enough to increase renal sodium excretion, but not potassium excretion. 24 Thus, disturbances in glucose and lipid metabolism are not apparent in patients treated with a low-dose diuretic due to the small decreases in serum potassium. In addition, the potassium-retaining effects of ARB resulting from decreases in aldosterone levels antagonize thiazide-induced hypokalemia. 25 In this study, serum potassium levels did not differ between the TH and Am groups. Hyperuricemia was observed more frequently in the TH group than in the Am group. However, in the TH group, higher levels of serum uric acid may have been overestimated because of a higher baseline value (P¼0.069). In the TH group, patients with treatment-induced hyperuricemia had relatively high baseline values of serum uric acid (X6.1 mg per 100 ml). The effects on uric acid excretion vary among the different ARBs. 26 In urate transporter 1 (URAT1)-expressing Xenopus oocytes, losartan and telmisartan showed cis-inhibitory effects on the uptake of uric acid, although telmisartan, which is not excreted into the renal tubule, cannot affect URAT1. On the other hand, candesartan showed a trans-stimulatory effect, whereas telmisartan did not. Thus, telmisartan does not modify the effects of thiazide diuretics to induce hyperuricemia. Therefore, it is suggested that low-dose hydrochlorothiazide, with or without combined telmisartan, should be carefully administered in patients with high normal serum uric acid, although serum uric acid is easily controlled by antihyperuricemic drugs.
In conclusion, combination therapy with telmisartan and low-dose hydrochlorothiazide is an antihypertensive treatment alternative in hypertensive patients with uncontrolled BP on CCB monotherapy because of its powerful depressor effect and less harmful effects on glucose and lipid metabolism. As appropriate BP reduction has an important role in the effects of antihypertensive drugs in preventing cardiovascular disease, the combination of a RAS inhibitor and a lowdose thiazide diuretic may be one of the most beneficial strategies for managing hypertension.
